Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr591.50 DKK
Change Today -18.50 / -3.03%
Volume 376.3K
As of 11:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - kr693.50
52 Week Low
10/16/14 - kr212.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. The company markets Ofatumumab, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia. Its products under development include Ofatumumab that is in Phase III clinical studies to treat follicular lymphoma and pemphigus vulgaris; and Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, as well as Daratumumab, a CD38 monoclonal antibody that is in Phase III clinical studies to treat multiple myeloma. The company’s products under development also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for active thyroid eye disease, as well as in Phase I clinical studies for diabetic macular edema. In addition, it has approximately 20 active pre-clinical pipeline programs, including naked antibodies, immune effector function enhanced antibodies, bispecific antibodies, and ADCs. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

179 Employees
Last Reported Date: 08/11/15
Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr11.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Compensation as of Fiscal Year 2014.

genmab a/s (GEN) Key Developments

Genmab A/S Enters an Agreement to Grant Novo Nordisk Commercial Licenses

Genmab A/S announced it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to create and develop bispecific antibody candidates for two therapeutic programs. The bispecific antibodies will target a disease area outside of cancer therapeutics. Under the terms of the agreement, Genmab will receive an upfront payment of USD 2 million from Novo Nordisk. After an initial period of exclusivity for the two target combinations, Novo Nordisk has an option to maintain exclusivity or take the licenses forward on a non-exclusive basis. Genmab is entitled to potential development, regulatory and sales milestones of up to approximately USD 250 million for each exclusive license, or approximately USD 200 million for each non-exclusive license. In addition, Genmab will be entitled to single-digit royalties on sales of any commercialized products.

Genmab Reports Earnings Results for the First Half of 2015; Reaffirms Revenue Guidance for 2015

Genmab reported earnings results for the first half of 2015. The company posted a 23% year-on-year revenue decline to DKK 281 million in the first half of 2015, compared to DKK 363 million in the first half of 2014. The decrease of DKK 82 million or 23% was mainly driven by lower milestone revenue under daratumumab collaboration with Janssen. Operating income was DKK 212 million in the first half of 2015 compared to DKK 65 million in the first half of 2014. The improvement of DKK 147 million was driven by the income from reversal of the ofatumumab funding liability of DKK 176 million combined with lower expenses, which were partly offset by decreased revenue. The company's revenue guidance for 2015 remains unchanged, at between USD 97.3 million and USD 112.2 million in total.

Genmab A/S - Special Call

Q&A Session with CEO


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr591.50 DKK -18.50

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €12.52 EUR -0.07
arGEN-X BV €10.13 EUR 0.00
MorphoSys AG €62.74 EUR -1.20
Seattle Genetics Inc $42.25 USD +1.01
XOMA Corp $0.86 USD +0.0388
View Industry Companies

Industry Analysis


Industry Average

Valuation GEN Industry Range
Price/Earnings 78.4x
Price/Sales 47.2x
Price/Book 13.1x
Price/Cash Flow 78.9x
TEV/Sales 43.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at